Human papillomavirus (HPV) is a leading cause of several types of cancer, including cervical, throat, head, neck, anal, penile, and vaginal cancers, posing a significant public health threat in the U.S. Cervical cancer alone is the fourth most common cancer in women globally, with an estimated 4,300 deaths projected in the U.S. in 2023.
Thankfully, the availability of an HPV vaccine provides crucial protection against the HPV strains responsible for most cervical and other HPV-associated cancers. With the potential to prevent over 90% of HPV-related cancers, the HPV vaccine is a major breakthrough in primary prevention.
However, despite the proven efficacy of both screening and the HPV vaccine, national rates for vaccination and screening still fall below optimal targets, and the situation worsened during the pandemic.
Join our Congressional Briefing: Preventing HPV-Related Cancers Through Vaccination and Screening to gain insights into the power of HPV vaccination, screening, and early treatment in combating multiple cancers, and to explore potential actions that Congress can take to promote increased usage of these essential tools across the country.
